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Colorectal cancer screening in Australia
Colorectal cancer is among the most common causes 
of cancer-related mortality. Between 1990 and 2013, 
global colorectal cancer-related mortality increased 
from 490 000 to 771 000 per annum.1 Our failure 
to systematically reduce incidence and mortality is 
remarkable because colorectal cancer is more fitted for 
population screening and prevention than any other 
malignancy. It has a long preclinical stage with treatable 
precursors, adenomatous, and serrated polyps.2 Polyp 
removal and treatment of early cancer improve disease 
outcome. The array of screening instruments continues 
to expand. The effect of screening on incidence and 
mortality has been extensively shown.3 Screening can be 
cost saving due to high disease incidence, low costs of 
some screening methods, and high costs of treatment 
for advanced cancer. 
The slow implementation of population screening 
in most countries relates to various issues that might 
differ per region.4 Effective screening requires political 
support, provision of information to the target 
population, resources, training of health professionals, 
and quality assurance. Effective implementation of 
population screening that is optimally adapted to 
any local situation can thus take many years. In the 
Netherlands for instance, 16 years were needed from 
initial preparation of pilot studies in 2002 to completed 
roll-out of a national screening programme in 2018.5 
With many potential screening strategies, among 
others varying in primary screening method, age range, 
and screening interval, it is very difficult to evaluate 
all options in practice in any individual country. This 
underscores the value of decision models. These models 
simulate a population over time and allow assessment 
of the effect of different screening strategies.6 
In The Lancet Public Health, Jie-Bin Lew and colleagues7 
modelled the future impact of the Australian colorectal 
cancer  screening programme on disease incidence 
and mortality.7 The programme consists of biennial 
faecal immunochemical testing (FIT) of 50–74 year-
old participants followed by colonoscopy in case of a 
haemoglobin concentration higher than 20 µg/g in the 
faeces.7 The programme started in 2006, with slow roll-
out despite an incidence of colorectal cancer among 
the highest in the world. Single-round participation 
is now 39%, and 70% of screenees with a positive FIT 
receive further assessment.8 The authors calculated 
that screening with 40% participation will prevent 
92 200 cancer cases and 59 000 deaths until 2040, 
and is highly cost effective. The authors also modelled 
other scenarios at different levels of participation. The 
forecasts under different scenarios are helpful, not only 
for Australia but also for other countries contemplating 
such a programme.
Lew and colleagues’ study7 provides important 
support for the further roll-out and continuation of the 
programme. This is a key message for the Australian 
population, politicians, and health-care providers. 
Despite its preventive effect, the model predicts that 
screening at the current participation level will not 
bring the number of colorectal cancer diagnoses and 
deaths per annum below current numbers. This should 
stimulate Australian public health professionals to 
find means to increase participation, which currently is 
lower compared with other colorectal cancer screening 
programmes and internationally accepted targets.9 
Indeed, the USA aim for 80% screening coverage of the 
target population by 2018, while European guidelines 
recommend an uptake of at least 65%.10
The study findings should also stimulate to reduce 
the current 30% failure rate to assess individuals with a 
positive FIT.8 Similar issues are encountered elsewhere, 
which underlines the relevance to share best practices.4 
Apart from these strengths, the study also has some 
limitations. Decision models are based on a range 
of assumptions regarding progression of neoplasia, 
efficacy, and costs of treatment, and screening accuracy 
and impact. Realistic predictions thus ask for extensive 
validation of the model against data from long-term 
prospective randomised screening trials, like has been 
done for other models.6,11 The decision model in this 
study seemed to lack this validation for the impact of 
screening.7 The predictions that screening can reduce 
colorectal cancer incidence and mortality, as well as 
reduce costs, are widely supported. But the magnitude 
of effect might differ. The model used by Lew and 
colleagues7 predicts that FIT screening with 60% 
participation might reduce overall colorectal cancer 
mortality with 40–45%, whereas available studies do 
not find a mortality reduction of more than 40% even 
if all eligible individuals in the population participate.12 
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Despite this limitation, we applaud Australia for 
monitoring and evaluating their cancer screening 
programme. These studies improve and optimise 
cancer screening,5 yet they are nevertheless lacking in 
most countries. In an effort to build capacity for such 
monitoring and evaluation, the Horizon 2020 funded 
EU-TOPIA project was launched, which will provide 
countries across Europe access to validated web-based 
monitoring and modelling instruments. 
In conclusion, Australia has high colorectal cancer 
incidence and mortality. The number of cancer cases and 
deaths would, without intervention, certainly further 
increase in the coming two decades. FIT screening 
can halt this increase, and save costs. It is therefore 
important that the roll-out of the FIT programme 
continues, and that measures are taken to increase its 
participation as well as assessment of screenees with a 
positive FIT. Policy makers and health-care providers 
should next look at additional interventions to further 
improve the impact of screening, for instance by 
lowering FIT cut-off.  
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